Research map: Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity

Back to the article

Papers in this map

  1. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity · Lalitha Iyer · 2002 · 721 citations · Cited by this paper
  2. Updated analysis of the pharmacogenomics of pediatric bronchodilator response · 2024 · Related
  3. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 · Hironobu Minami · 2007 · 292 citations · Cited by this paper
  4. Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation · 2025 · Related
  5. Organic anion transporting polypeptide 1a/1b–knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs · Evita van de Steeg · 2010 · 229 citations · Cited by this paper
  6. Pharmacogenomics of commonly used intravenous anesthetics · 2025 · Related
  7. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin · Óscar Briz · 2003 · 175 citations · Cited by this paper
  8. Application of risk priority number of failure mode and effects analysis to drug–variant pairs for severe cutaneous adverse reactions in Korean and American populations · 2026 · Related
  9. Pharmacogenomics Clinical Annotation Tool (Pharm CAT ) · Katrin Sangkuhl · 2019 · 130 citations · Cited by this paper
  10. Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity · 2025 · Related
  11. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors · Antoinette R. Tan · 2013 · 112 citations · Cited by this paper
  12. Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch–Schönlein purpura nephritis · 2026 · Related
  13. The Michigan Genomics Initiative: A biobank linking genotypes and electronic clinical records in Michigan Medicine patients · Matthew Zawistowski · 2023 · 104 citations · Cited by this paper
  14. Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma · 2024 · Related
  15. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients · Petra Bohanec Grabar · 2008 · 93 citations · Cited by this paper
  16. Association of estrogen and progesterone receptor polymorphisms with idiopathic thin endometrium · 2025 · Related
  17. Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants · Chiaki Tanaka · 2010 · 69 citations · Cited by this paper
  18. No interaction between genetic variants and DNA methylation of the ferrochelatase gene in relation to antituberculosis drug-induced liver injury · 2025 · Related
  19. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation · Ryan Nelson · 2021 · 69 citations · Cited by this paper
  20. Individualized perampanel response and efficacy in patients with refractory epilepsy: the need for ATP-binding cassette B1 genotyping and therapeutic drug monitoring to work in tandem · 2026 · Related
  21. Effects of Common CYP 1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis · Dandan Tian · 2018 · 55 citations · Cited by this paper
  22. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors · Varun Khurana · 2014 · 45 citations · Cited by this paper
  23. Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia · Maiko Abumiya · 2014 · 43 citations · Cited by this paper
  24. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms · Robert John Motzer · 2013 · 39 citations · Cited by this paper
  25. Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients · Sander Bins · 2018 · 30 citations · Cited by this paper
  26. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors · Camille Azam · 2020 · 19 citations · Cited by this paper
  27. Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain · Adrián Bravo-Gómez · 2022 · 16 citations · Cited by this paper
  28. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors · Michiel C. Verboom · 2019 · 12 citations · Cited by this paper
  29. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro · Mingming Han · 2021 · 11 citations · Cited by this paper
  30. Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen · Thomas Drabison · 2024 · 10 citations · Cited by this paper

Source: OpenAlex (CC0)